Literature DB >> 26787367

Risk factors for cardiovascular disease and mortality events in adults with type 2 diabetes - a 10-year follow-up: Tehran Lipid and Glucose Study.

Sheila Afsharian1, Samaneh Akbarpour1, Hengameh Abdi2, Farhad Sheikholeslami1, Ali Siamak Moeini1, Davood Khalili1, Amir Abbas Momenan1, Fereidoun Azizi2, Farzad Hadaegh1.   

Abstract

BACKGROUND: To identify risk factors for cardiovascular disease (CVD) and mortality events in patients with type 2 diabetes and to calculate their population attributable fraction among a representative Iranian population.
METHODS: A total of 1198 patients with type 2 diabetes (504 men and 694 women), aged ≥30 years, without prevalent CVD, with a median follow-up of 10 years were included in current study. To examine the association between risk factors and their outcomes, multivariate sex-adjusted Cox proportional hazard regression models were used.
RESULTS: During the study, 281 and 172 participants experienced CVD and all-cause mortality events, respectively. Regarding CVD events, fasting plasma glucose (FPG) level of 7.22-<10 mmol/L [hazard ratio (HR): 1.46, 95% CI 1.12-1.96], FPG level ≥10 mmol/L (HR 2.04, 1.53-2.72), hypertension (HR 1.65, 1.28-2.13), hypercholesterolaemia (HR 1.96, 1.40-2.75) and high waist to hip ratio (HR 1.30, 0.99-1.70; p = 0.051) were significant predictors, and corresponding population attributable fractions were 9.76, 17.84, 23.26, 41.63 and 14.76%, respectively. Considering all-cause mortality events, hypertension (HR 1.70, 1.23-2.36), FPG level ≥10 mmol/L (HR 2.31, 1.55-3.20) and smoking (HR 1.45, 1.03-2.04) were significant predictors, and corresponding population attributable fractions were 25.81, 20.88 and 11.18%, respectively. Meanwhile, being overweight or obese was associated with lower all-cause and CVD mortality events.
CONCLUSIONS: Among modifiable risk factors in patients with type 2 diabetes, hypercholesterolaemia and central adiposity for CVD, smoking for mortality events and hypertension and poor glycaemic control for both outcomes need to be paid most attention by healthcare professionals.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  cardiovascular disease; health policy; mortality; risk factors; type 2 diabetes

Mesh:

Substances:

Year:  2016        PMID: 26787367     DOI: 10.1002/dmrr.2776

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  11 in total

1.  Different combinations of glucose tolerance and blood pressure status and incident cardiovascular disease and all-cause mortality events.

Authors:  M A Hajebrahimi; S Akbarpour; A Eslami; F Azizi; F Hadaegh
Journal:  J Hum Hypertens       Date:  2017-07-27       Impact factor: 3.012

2.  A genetic variant in the catechol-O-methyl transferase (COMT) gene is related to age-dependent differences in the therapeutic effect of calcium-channel blockers.

Authors:  Jiayue Xu; Adrian E Boström; Mohamed Saeed; Raghvendra K Dubey; Gérard Waeber; Peter Vollenweider; Pedro Marques-Vidal; Jessica Mwinyi; Helgi B Schiöth
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

Review 3.  Tobacco Smoking: Findings from 20 Years of the Tehran Lipid and Glucose Study.

Authors:  Donna Parizadeh; Amir Abbas Momenan; Atieh Amouzegar; Fereidoun Azizi; Farzad Hadaegh
Journal:  Int J Endocrinol Metab       Date:  2018-10-31

Review 4.  Diabetes Mellitus: Findings from 20 Years of the Tehran Lipid and Glucose Study.

Authors:  Azra Ramezankhani; Hadi Harati; Mohammadreza Bozorgmanesh; Maryam Tohidi; Davood Khalili; Fereidoun Azizi; Farzad Hadaegh
Journal:  Int J Endocrinol Metab       Date:  2018-10-16

5.  Lipoprotein(a) Concentrations Correlate With LDL-C in Children With Type 1 and 2 Diabetes.

Authors:  Christy Foster; A K M Fazlur Rahman; Ambika P Ashraf
Journal:  J Endocr Soc       Date:  2021-08-18

Review 6.  Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: Expert recommendations.

Authors:  Alper Sonmez; Hani Sabbour; Akram Echtay; Abbas Mahdi Rahmah; Amani Matook Alhozali; Fahad Sulman Al Sabaan; Fares H Haddad; Hinde Iraqi; Ibrahim Elebrashy; Samir N Assaad; Zaheer Bayat; Zeynep Osar Siva; Mohamed Hassanein
Journal:  J Diabetes       Date:  2022-04-17       Impact factor: 4.530

Review 7.  Coadjuvants in the Diabetic Complications: Nutraceuticals and Drugs with Pleiotropic Effects.

Authors:  Thiago Melo Costa Pereira; Fabio Silva Pimenta; Marcella Lima Porto; Marcelo Perim Baldo; Bianca Prandi Campagnaro; Agata Lages Gava; Silvana Santos Meyrelles; Elisardo Corral Vasquez
Journal:  Int J Mol Sci       Date:  2016-08-05       Impact factor: 5.923

8.  Effects of pioglitazone treatment on blood leptin levels in patients with type 2 diabetes.

Authors:  Satoshi Ida; Kazuya Murata; Ryutaro Kaneko
Journal:  J Diabetes Investig       Date:  2017-12-25       Impact factor: 4.232

9.  Relationships of diabetes self-care behaviours to glycaemic control in adults with type 2 diabetes and comorbid heart failure.

Authors:  Fekadu Aga; Sandra B Dunbar; Tedla Kebede; Melinda Kay Higgins; Rebecca Gary
Journal:  Nurs Open       Date:  2020-06-15

10.  Aggregation and combination of cardiovascular risk factors and their association with 10-year all-cause mortality: the PERU MIGRANT Study.

Authors:  Janina Bazalar-Palacios; J Jaime Miranda; Rodrigo M Carrillo-Larco; Robert H Gilman; Liam Smeeth; Antonio Bernabe-Ortiz
Journal:  BMC Cardiovasc Disord       Date:  2021-12-07       Impact factor: 2.174

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.